Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data

Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data

IntroductionAnaplastic lymphoma kinase (ALK) inhibitors (ALKi) are the standard treatment for metastatic, ALK-positive non-small cell lung cancer (NSCLC). Second- and third-generation ALKi, including alectinib, brigatinib, ensartinib, envonalkib, and lorlatinib, have shown better efficacy than crizo...

Full description

Saved in:
Bibliographic Details
Main Authors: Vera Damuzzo, Lorenzo Gasperoni, Luna Del Bono, Andrea Ossato, Alessandro Inno, Andrea Messori
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Oncology
Subjects:
NSCLC
ALK-inhibitors
IPDfromKM
indirect comparison
Shiny method
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1566816/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2025.1566816/full

Similar Items